New drug duo shows promise against tough cancers
NCT ID NCT04322006
First seen May 16, 2026 · Last updated May 16, 2026
Summary
This study tested a new drug (TJ004309) alone or with another drug (Toripalimab) in 225 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to find the safest and most effective dose, and to see if the combination could shrink tumors or slow their growth. While not a cure, this approach aims to control the disease and improve outcomes for people with few options left.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Army Medical Center of PLA
Chongqing, Chongqing Municipality, China
-
Cancer Hospital affiliated to Shantou University Medical College
Shantou, Guangdong, China
-
Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
-
Chongqing Cancer Hospital
Chongqing, Chongqing Municipality, China
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200032, China
-
Guangdong Provincial Hospital of Chinese Medicine
Guangzhou, Guangdong, China
-
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, 510080, China
-
Harbin Medical University Cancer Hospital
Haerbin, Heilongjiang, China
-
Henan Cancer Hospital
Zhengzhou, Henan, China
-
Hubei Cancer Hospital
Wuhan, Hubei, China
-
Hunan Cancer Hospital
Changsha, Hunan, China
-
Liaoning Cancer Hospital and Institute
Shenyang, Liaoning, China
-
Northern Jiangsu People's Hospital
Yangzhou, Jiangsu, China
-
Sichuan Cancer Hospital
Chengdu, Sichuan, China
-
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
Hanzhou, Zhejiang, China
-
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China
-
The First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, China
-
The First Affiliated Hospital of Xi 'an Jiaotong University
Xi'an, Shaanxi, China
-
The First Bethune Hospital of Jilin University
Changchun, Jilin, 130021, China
-
The First Hospital of China Medical University
Shenyang, Liaoning, China
-
The Second Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
-
Yunnan Cancer Hospital
Kunming, Yunnan, China
Conditions
Explore the condition pages connected to this study.